Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
Minimal By Design: Define MSE Endpoints
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
The 2-Point Signal: Apply ≥2-Point Rule
Escalate With Intention: Stepwise, Target-Anchored Moves
The IgG Clock: Redose Using IgG Kinetics
Shared Goals, Shared Gains: Align With Patient Preferences
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
IgAN SOC: Strengths and Limits
Dana Rizk, MD
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cristina Rodriguez, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.